United States · FDA National Drug Code directory

Lamzede

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
10122-180_27cf090b-196e-4330-8184-c72d9bb90660
Product NDC
10122-180
Form
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Composition / generic term
Velmanase alfa-tycv
Labeler
Chiesi USA, Inc.
Marketing category
BLA
Marketing start / end (source format)
20230301
Source listing expiry
20261231

Source-listed ingredients

  • VELMANASE ALFA-TYCV — 10 mg/1

These values do not establish equivalence or a dose recommendation.

Packages

  • 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (10122-180-02) · 10122-180-02
  • 5 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (10122-180-05) · 10122-180-05
  • 10 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (10122-180-10) · 10122-180-10

Source and coverage

Open FDA National Drug Code directory

Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse United States records →